drugset
drugset / Trial / NCT06009094

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

NCT06009094 ↗

Phase 1 Completed 80 enrolled Jiangsu vcare pharmaceutical technology co., LTD
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a single center, randomized, double-blind, Vehicle controlled,, single and multiple dose clinical study.

Timeline

Start
2023-07-27
Primary completion
2024-05-23
Completion
2024-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject VC005 Unknown — Topical

Indications

atopic eczema